Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: Application to acetaminophen injury

Toxicology and Applied Pharmacology

Volumn 259, Issue 3, 2012, Pages 270-280

  Prot, Jean Matthieu ^a   Bunescu, Andrei ^b   Elena Herrmann, Bénédicte ^b   Aninat, Caroline ^c,d   Snouber, Leila Choucha ^a   Griscom, Laurent ^f   Razan, Florence ^f   Bois, Frederic Y ^e   Legallais, Cécile ^a   Brochot, Céline ^d   Corlu, Anne ^c   Dumas, Marc Emmanuel ^b,g   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Univ Rennes   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^f CNRS   (France)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acetaminophen; Biomarkers identification; Liver tissue engineering; Metabolomic; Microfluidic biochip; PDMS; Predictive toxicology; Proteomic; Transcriptomic

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; 3 HYDROXYBUTYRIC ACID; ACTIN; CYSTINE; GLUTATHIONE; HISTIDINE; KERATIN; KHELLIN; METHIONINE; N ACETYL 1,4 BENZOQUINONE IMINE; PARACETAMOL; PROTEIN; TUBULIN;

APOPTOSIS; ARTICLE; BIOCHIP; CALCIUM HOMEOSTASIS; CELL CYCLE ARREST; CELL DEATH; CONJUGATION; CYTOSKELETON; DETOXIFICATION; DNA DAMAGE; DRUG METABOLISM; FATTY ACID METABOLISM; HEPATOMA CELL; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; LIVER TOXICITY; METABOLOMICS; MICROENVIRONMENT; MICROFLUIDICS; MOLECULAR BIOLOGY; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; BENZOQUINONES; CYTOPROTECTION; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION PROFILING; HEP G2 CELLS; HUMANS; IMINES; METABOLOMICS; MICROFLUIDIC ANALYTICAL TECHNIQUES; OXIDATIVE STRESS; PROTEOMICS;

EID: 84858069327     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.12.017     Document Type: Article

References (42)

1. Baudoin R., Corlu A., Griscom L., Legallais C., Leclerc E. Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicol. In Vitro 2007, 21:535-544.
2. Baudoin R., Griscom L., Prot J.M., Legallais C., Leclerc E. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochem. Eng. J. 2011, 53:172-181.
3. Beger R., Sun J., Schnackenberg L. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2010, 243:154-166.
4. Boudonck K., Mitchell M., Nemet L., Keresztes L., Nyska A., Shinar D., Rosenstock M. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 2009, 37:280-292.
5. Boverhof D.R., Burgoon L.D., Tashiro C., Sharratt B., Chittim B., Harkema J.R., et al. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol. Sci. 2006, 94:398-416.
6. Bugrim A., Nikolskaya T., Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today 2004, 9(3):127-135.
7. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., Guertin D.A., Chang J.H., Lindquist R.A., Moffat J., Golland P., Sabatini D.M. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006, 7:100-111.
8. Chao P., Maguire T., Novik E., Cheng K.C., Yarmush M.L. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 2009, 78:625-632.
9. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1-13.
10. Chiu, W.A., Euling, S.Y., Siegel Scott, C., Subramaniam, R.P., in press. Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post genomic era. Toxicol. Appl. Pharmacol.
11. Clayton T.A., et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440:1073-1077.
12. Coen M., Ruepp S.U., Lindon J.C., Nicholson J.K., Pognan F., Lenz E.M., Wilson I.D. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J. Pharm. Biomed. Anal. 2004, 35:93-105.
13. Cullingford T.E., Dolphin C.T., Sato H. The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain. Neuropharmacology 2002, 42:724-730.
14. De Bartolo L., Bader A. Review of a flat membrane bioreactor as a bioartificial liver. Ann. Transplant. 2001, 6:40-46.
15. De Kanter R., Monshouwer M., Meijer D., Groothuis G. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Adapt. Curr. Drug Metabol. 2002, 3:39-59.
16. Dumas M.E., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12511-12516.
17. Dumas M.E., et al. Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat. Genet. 2007, 39:666-672.
18. Figeys D. Combining different 'omics' technologies to map and validate protein-protein interactions in humans. Brief. Funct. Genomic. Proteomic. 2004, 2:357-365.
19. Franklin M.R., Yost G.S. Biotransformation: a balance between bioactivation and detoxification. Principles of Toxicology: Environmental and Industrial Applications 2000, 57-86. John Wiley & Sons, New York, NY. P.L. Williams, R.C. James, S.M. Roberts (Eds.).
20. Fukao T., Lopaschuk G.D., Mitchell G.A. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:243-251.
21. Gall W., Beebe K., Lawton K., Adam K.P., Mitchell M., Nakhle P., Ryals J., Milburn M., Nannipieri M., Camastra S., Natali A., Ferrannini E. a-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 2010, 5:e10883.
22. Gebhardt R., Hengstler J.G., Muller D., Glockner R., Buenning P., Laube B., Schmelzer E., Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B.R., Bader A., Langsch A., Koose T., Burger H.J., Maas J., Oesch F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 2003, 35:145-213.
23. Guillouzo A. Liver cell models in in vitro toxicology. Environ. Health Respect. 1998, 106:511-532.
24. Guillouzo A. New perspectives in the use of human hepatocytes in the preclinical drug development process. Ann. Pharm. Fr. 2008, 66:288-295.
25. Griffith L., Naughton G. Tissue Engineering-current challenges and expanding opportunities. Science 2002, 295:1009-1014.
26. Ierapetritou M.G., Georgopoulos P.G., Roth C.M., Androulakis I.P. Tissue-level modeling of xenobiotic metabolism in liver: an emerging tool for enabling clinical translational research. Clin. Transl. Sci. 2009, 2:228-237.
27. Kanehisa M., Goto S., Furumichi M., Tanabe M., Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38:355-360.
28. Novik E., Maguire T.J., Chao P., Cheng K.C., Yarmush M.L. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem. Pharmacol. 2010, 79:1036-1044.
29. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1:153-161.
30. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
31. Madalinski G., Godat E., Alves S., Lesage D., Genin E., Levi P., Labarre J., Tabet J.C., Ezan E., Junot C. Direct introduction of biological samples into a LTQ-Orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis. Anal. Chem. 2008, 80:3291-3303.
32. Park S., Kim S.H.J., Ropella G.E.P., Robert M.S., Hunt C.A. Tracing multiscale mechanisms of drug disposition in normal and diseased livers. J. Pharmacol. Exp. Ther. 2010, 334:124-136.
33. Powers M.J., Janigan D., Wack K.E., Baker Stolz D.B., Griffith L. Functional behavior of primary Rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng. 2002, 8:499-508.
34. Prot J.M., Aninat C., Griscom L., Razan F., Brochot C., Guguen Guillouzo C., Legallais C., Corlu A., Leclerc E. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol. Bioeng. 2011, 108:1704-1715.
35. Prot J.M., Videau O., Brochot C., Legallais C., Benech H., Leclerc E. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int. J. Pharma. 2011, 408:67-75.
36. Prot J.M., Briffaut A.S., Letourneur F., Chafey P., Merlier F., Grandvalet Y., Legallais C., Leclerc E. Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip. Plos One 2011, 6:21268-21278.
37. Ruepp S., Tonge R., Shaw J., Wallis N., Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 2002, 65:135-150.
38. Sivaraman A., Leach J.K., Townsend S., Iida T., Hogan B.J., Stolz D.B., Fry R., Samson L.D., Tannenbaum S.R., Griffith L.G. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr. Drug Metab. 2005, 6:569-592.
39. Stephens J.M., Pekala P.H. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J. Biol. Chem. 1991, 266:21839-21845.
40. Soga T., Baran R., Suematsu M., Ueno Y., Ikeda S., Sakurakawa T., Kakazu Y., Ishikawa T., Robert M., Nishioka T., Tomita M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 2006, 281:16768-16776.
41. Teague C.R., Dhabhar F.S., Barton R.H., Beckwith-Hall B., Powell J., Cobain M., Singer B., McEwen B.S., Lindon J.C., Nicholson J.K., Holmes E. Metabonomic studies on the physiological effects of acute and chronic psychological stress in Sprague-Dawley rats. J. Proteome Res. 2007, 6:2080-2093.
42. Yu X., Pandey S.K., Booten S.L., Murray S.F., Monia B.P., Bhanot S. Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E530-E539.